Nature Communications (Feb 2019)
A platform for glycoengineering a polyvalent pneumococcal bioconjugate vaccine using E. coli as a host
Abstract
Bioconjugation is a promising process to manufacture conjugate vaccines, but currently employed enzymes cannot generate the full spectrum of bacterial glycoproteins. Here, the authors use an O-linking oligosaccharyltransferase to generate a polyvalent pneumococcal bioconjugate vaccine with polysaccharides containing glucose at their reducing end.